Tag: slow-declines

  • Lilly’s drug for Alzheimer’s fails big trial; shares drop

    The failure of Eli Lilly and Co’s Alzheimer’s treatment to slow declines in mental capacity of patients with even mild symptoms cast serious doubt over whether a long-held approach to the memory-robbing disease could provide meaningful benefit to millions of people at risk. Many investors and families had been counting on solanezumab to become the…